Short-Term Debt to Capital: STAAR Surgical Co. (STAA)

Corporate company logo of STAAR Surgical Company (STAA)

Historical price action on the GURU.Markets platform confirms the effectiveness of STAAR Surgical Company (STAA) management, which ensures supply chain transparency and expansion in Asia. The current indicator is 0.02. The business relies on the demand for ophthalmological implants and the certification of new materials. Profit growth is driven by a global increase in myopia cases, which expands the company's product sales in the Asia-Pacific region.

STAA - STAAR Surgical Co. Short-Term Debt to Capital Coefficient over the range 07/04/2022 - 11/01/2026

Analytical breakdowns for STAAR Surgical Company

- stock quotes and analyst forecast:
Stock Price STAAR Surgical Corp|STAA - Average Forecast Price
- company stock exchange capitalization indicators:
Market Capitalization STAAR Surgical Co.|STAA - Business Value
- book capitalization information:
Book Value per Share STAAR Surgical|STAA - Book Valuation of Business|Market Capitalization to Book Value Ratio staar.com|STAA - Cumulative Company Assets
- business debt structure and liquidity details:
Total Debt to Capital STAAR Surgical Company|STAA - Long-Term Debt to Capital|Short-Term Debt to Equity STAAR Surgical|STAA - Company Debts|Debt to Book Value STAAR Surgical Co.|STAA - Company Long-Term Loans and Borrowings|Company Short-Term Debts STAAR Surgical|Quick Liquidity staar.com
- earnings and market ratios statistics:
STAA - Company Profit
General company analysis:STAAR Surgical Corp STAA
Brand item of STAAR Surgical

As a recognized innovator in ophthalmologic surgery with premium product quality, STAAR Surgical Company can leverage debt capital to scale its technologies. This short-term debt-to-equity ratio compares liabilities with maturities exceeding one year against net shareholder assets, determining the business's degree of financial autonomy. The declining values on this chart confirm the stability of the balance sheet structure and the protection of investments from dilution.

Direct competitors

Short-Term Debt to Capital ISRG|DHR - Current Liabilities to Capital|Short-Term Debt to Capital BDX (Becton Dickinson & Co)|STE: Short-Term Debt to Capital Ratio|West Pharmaceutical Services, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Baxter International Inc. BAX|MASI: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Stevanato Group Corp|TFX (Teleflex Incorporated) - Short-Term Debt to Capital|Short-Term Debt to Capital merit.com|Short-Term Debt to Equity Envista (NVST)|Short-Term Debt to Equity ICUI (ICU Medical Inc)|Dentsply - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital LMAT|AtriCure, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient ChromaDex Corp NAGE|ZimVie (ZIMV) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio ANGO|Short-Term Debt to Equity Cerus Corp|Teknova Inc (TKNO) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio MGRM (Monogram Technologies)|Short-Term Loans to Capital Ratio STSS|Short-Term Debt to Equity InfuSystem Holdings, Inc. INFU|Ratio of Short-Term Indebtedness to Capital UTMD|KRMD: Short-Term Debt to Equity Ratio|NYXH - Short-Term Debt to Capital|Microbot Medical Inc. (MBOT) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio pro-dex.com|ZTEK (Zentek) - Short-Term Debt to Capital|Current Liabilities to Capital Elutia Inc ELUT|Short-Term Debt to Equity Milestone Scientific Corp (MLSS)|NEXGEL Inc - Short-Term Debt to Capital Ratio|Retractable Technologies, Inc. - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio HBIO (Harvard Bioscience Inc.)|FEMY - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient MeihuaMed MHUA|predictive-oncology.com (POAI) - Short-Term Debt to Equity|CJMB - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio ATRI|NURO (neurometrix.com) - Short-Term Loans to Capital Ratio